Abstract: This disclosure provides more effective and/or efficient techniques for implementing redundancy. For example, some techniques include a voting service that receives output from processes executing on three different hardware devices to determine which output to provide to a consumer of the output. Such techniques are optimized through where the voting service is located, what is received by the voting service, how processes are executed on the three different hardware devices, and how output is provided to the consumer, as further discussed herein. Such techniques optionally complement or replace other methods for implementing redundancy.

Abstract: A system and method for managing temperature internal to a Wireless Power Transfer (WPT) system for electric vehicles is provided. The thermal management system of the WPT system uses one or more of passive, semi-active, and active cooling approaches to manage the internal temperatures of the WPT system during a charging session. Improvements in thermal management allow for longer duration charging sessions and higher power charging sessions without the need to suspend charging for cool-down. Further, several different approaches to disguising and implementing the thermal management system in public spaces is also provided.

Abstract: A fuel-fired heating appliance comprises a fuel source, an air source, a chamber in which fuel and air mix, a burner downstream from the mixing chamber, an igniter proximate the burner, a heat exchanger, a blower and a flue pipe. An ambient air inlet may be defined by at least one of the outlet end of the blower and the flue pipe extending between the interior of the flue pipe and an area ambient to the flue pipe. A flow rate of combustion gas may be controlled to a level below a steady-state flow rate during appliance warm-up.

Abstract: An apparatus for cryostorage and manipulation of a plurality of container units includes a cryochamber having a cryo-access port. The cryochamber is electrically cooled at cryogenic temperatures. A unit holder is located inside the cryochamber and is configured to hold a plurality of container units. A user access area is provided for selectively permitting access to a chosen container unit by an authenticated user who has been authenticated by the apparatus. A motive grasper is provided for selectively removing the chosen container unit from the cryochamber through the cryo-access port, and selectively placing the chosen container unit into the user access area.

Abstract: The invention relates to neuroprotection and to medicaments for use therein. Neuroprotection is induced by activation of neural growth hormone receptors, primarily using medicaments comprising growth hormone, growth hormone analogs or ligands which are functionally equivalent. Such medicaments may also include one or more secondary neuroprotective agents.

Abstract: A method for treatment or prophylaxis of a patient suffering from functional symptoms of Parkinson's disease, especially as a consequence of damage to dopaminergic neurons, by administering to the patient a neuroprotective amount of a peptide selected from the tripeptide gly-pro-glu (GPE) and analogs and mimetics thereof, preferably GPE. The GPE will usually be administered subsequent to the onset of Parkinson's disease but prior to the damage of said dopaminergic neurons.

Abstract: An intelligent brain rescue instrument for identifying, monitoring, and guiding the application of brain therapies to patients with evolving brain injuries, comprises an input for acquiring a multiple number of signals each indicative of a different biochemical or biophysical parameter of a patient, and a computer to continuously sample each of the acquired signals and display to a user on a monitor at least some of the parameters. The displayed parameters are selected by system software embodying expert analytical rules as the most significant parameters, or as parameters having values indicative, or predictive at any time of actual, or potential future deterioration of the brain state of the patient.

Abstract: The tripeptide glycine-proline-glutamine (GPE) may be administered before, or usually after, injury to reduce damage to the central nervous system. GPE appears useful for neuronal rescue particularly but not exclusively within the hippocampus. Advantages of GPE include: (a) that it crosses the blood-brain barrier, so is effective by injected peripheral administration, (b) it is unlikely to challenge the immune system, (c) it is cheap, and (d) its therapeutic ratio is high. GPE may also be infused into the CSF. It may be administered prior to parturition or elective brain or cardiac surgery. Transdermal routes may be useful for chronic neural disorders. The CNS of mammals (including foetal mammals) after trauma including hypoxic/ischaemic experimental insults showed reduced damage under GPE protection as measured by histological assessment of cell damage or death and regional shrinkage.

Abstract: An intelligent brain rescue instrument for identifying, monitoring, and guiding the application of brain therapies to patients with evolving brain injuries, comprises input means (101-103) for acquiring a multiple number of signals each indicative of a different biochemical or biophysical parameter of a patient, computing means (104-107) to continuously sample each of the acquired signals and display to a user on a monitor (109) at least some of the parameters, the displayed parameters being selected by system software embodying expert analytical rules as the most significant parameters, or as parameters having values indicative, or predictive at any time of actual, or potential future deterioration of the brain state of the patient.

Abstract: An intelligent brain rescue instrument for identifying, monitoring, and guiding the application of brain therapies to patients with evolving brain injuries, includes an input for acquiring a multiple number of signals each indicative of a different biochemical or biophysical parameter of a patient, a computer to continuously sample each of the acquired signals and display to a user on a monitor at least some of the parameters, the displayed parameters being selected by system software embodying expert analytical rules as the most significant parameters, or as parameters having values indicative, or predictive at any time of actual, or potential future deterioration of the brain state of the patient.

Abstract: This invention relates to the use of the tripeptide Gly-Pro-Glu (GPE) or analogs thereof for the treatment of conditions of the central nervous system (e.g. cerebral vasculitis) in which the amount of the neural enzymes nitric oxide synthetase (NOS) and/or glutamic acid decarboxylase (GAD) is reduced.

Abstract: A method for treatment or prophylaxis of a patient suffering from functional symptoms of Parkinson's disease, especially as a consequence of damage to dopaminergic neurons, by administering to the patient a neuroprotective amount of a peptide selected from the tripeptide gly-pro-glu (GPE) and analogs and mimetics thereof, preferably GPE. The GPE will usually be administered subsequent to the onset of Parkinson's disease but prior to the damage of said dopaminergic neurons.

Abstract: The tripeptide glycine-proline-glutamine (GPE) may be administered before, or usually after, injury to reduce damage to the central nervous system. GPE appears useful for neuronal rescue particularly but not exclusively within the hippocampus. Advantages of GPE include: (a) that it crosses the blood-brain barrier, so is effective by injected peripheral administration, (b) it is unlikely to challenge the immune system, (c) it is cheap, and (d) its therapeutic ratio is high. GPE may also be infused into the CSF. It may be administered prior to parturition or elective brain or cardiac surgery. Transdermal routes may be useful for chronic neural disorders. The CNS of mammals (including foetal mammals) after trauma including hypoxic/ischaemic experimental insults showed reduced damage under GPE protection as measured by histological assessment of cell damage or death and regional shrinkage.

Abstract: Disclosed herein is a method for protecting dopaminergic neurons of a mammal against death resulting from Parkinson's disease. The method comprises administering a neuroprotective amount of the tripeptide Gly-Pro-Glu.